Gewillig, M. The Fontan circulation. Heart
2005; 91: 839–846.
Driscoll, DJ, Offord, KP, Feldt, RH, Schaff, HV, Puga, FJ, Danielson, GK. Five- to fifteen-year follow-up after Fontan operation. Circulation
1992; 85: 469–496.
Gentles, TL, Gauvreau, K, Mayer, JE Jr, et al. Functional outcome after the Fontan operation: factors influencing late morbidity. J Thorac Cardiovasc Surg
1997; 114: 392–403; discussion 4–5.
d’Udekem, Y, Iyengar, AJ, Galati, J, et al. Redefining expectations of long-term survival after the Fontan procedure: twenty-five years of follow-up from the entire population of Australia and New Zealand. Circulation
2014; 130 (Suppl 1): S32–S38.
Deal, BJ, Jacobs, ML. Management of the failing Fontan circulation. Heart
2012; 98: 1098–1104.
Giardini, A, Hager, A, Pace Napoleone, C, Picchio, FM. Natural history of exercise capacity after the Fontan operation: a longitudinal study. Ann Thorac Surg
2008; 85: 818–821.
Stickland, MK, Welsh, RC, Petersen, SR, et al. Does fitness level modulate the cardiovascular hemodynamic response to exercise?
J Appl Physiol
2006; 100: 1895–1901.
Goldberg, DJ, Avitabile, CM, McBride, MG, Paridon, SM. Exercise capacity in the Fontan circulation. Cardiol Young
2013; 23: 824–830.
Caruthers, RL, Kempa, M, Loo, A, et al. Demographic characteristics and estimated prevalence of Fontan-associated plastic bronchitis. Pediatr Cardiol
2013; 34: 256–261.
Feldt, RH, Driscoll, DJ, Offord, KP, et al. Protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg
1996; 112: 672–680.
Ghanayem, NS, Berger, S, Tweddell, JS. Medical management of the failing Fontan. Pediatr Cardiol
2007; 28: 465–471.
Anderson, PA, Breitbart, RE, McCrindle, BW, et al. The Fontan patient: inconsistencies in medication therapy across seven pediatric heart network centers. Pediatr Cardiol
2010; 31: 1219–1228.
Moher, D, Liberati, A, Tetzlaff, J, Altman, DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol
2009; 62: 1006–1012.
Higgins, JPT, Green, S. Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0. The Cochrane collaboration, 2011. Retrieved from www.cochrane-handbookorg.
Goldberg, DJ, French, B, McBride, MG, et al. Impact of oral sildenafil on exercise performance in children and young adults after the Fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation
2011; 123: 1185–1193.
Goldberg, DJ, French, B, Szwast, AL, et al. Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation. Pediatr Cardiol
2012; 33: 689–696.
Tunks, RD, Barker, PC, Benjamin, DK Jr, et al. Sildenafil exposure and hemodynamic effect after Fontan surgery. Pediatr Crit Care Med
2014; 15: 28–34.
Kouatli, AA, Garcia, JA, Zellers, TM, Weinstein, EM, Mahony, L. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation
1997; 96: 1507–1512.
Rhodes, J, Ubeda-Tikkanen, A, Clair, M, et al. Effect of inhaled iloprost on the exercise function of Fontan patients: a demonstration of concept. Int J Cardiol
2013; 168: 2435–2440.
Hebert, A, Mikkelsen, UR, Thilen, U, et al. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study. Circulation
2014; 130: 2021–2030.
Giardini, A, Balducci, A, Specchia, S, Gargiulo, G, Bonvicini, M, Picchio, FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J
2008; 29: 1681–1687.
Schuuring, MJ, Vis, JC, van Dijk, AP, et al. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail
2013; 15: 690–698.
Hager, A, Weber, R, Muller, J, Hess, J. Predictors of sildenafil effects on exercise capacity in adolescents and adults with Fontan circulation. Clin Res Cardiol
2014; 103: 641–646.
Ovaert, C, Thijs, D, Dewolf, D, et al. The effect of bosentan in patients with a failing Fontan circulation. Cardiol Young
2009; 19: 331–339.
Van De Bruaene, A, La Gerche, A, Claessen, G, et al. Sildenafil improves exercise hemodynamics in Fontan patients. Circ Cardiovasc Imaging
2014; 7: 265–273.
Kempny, A, Dimopoulos, K, Uebing, A, et al. Reference values for exercise limitations among adults with congenital heart disease. Relation to activities of daily life – single centre experience and review of published data. Eur Heart J
2012; 33: 1386–1396.
Diller, GP, Giardini, A, Dimopoulos, K, et al. Predictors of morbidity and mortality in contemporary Fontan patients: results from a multicenter study including cardiopulmonary exercise testing in 321 patients. Eur Heart J
2010; 31: 3073–3083.
Argiento, P, Chesler, N, Mule, M, et al. Exercise stress echocardiography for the study of the pulmonary circulation. Eur Respir J
2010; 35: 1273–1278.
Khambadkone, S, Li, J, de Leval, MR, Cullen, S, Deanfield, JE, Redington, AN. Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation
2003; 107: 3204–3208.
Nemoto, S, Sasaki, T, Ozawa, H, et al. Oral sildenafil for persistent pulmonary hypertension early after congenital cardiac surgery in children. Eur J Cardiothorac Surg
2010; 38: 71–77.
Duffels, MG, van der Plas, MN, Surie, S, et al. Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism. Neth Heart J
2009; 17: 334–338.
Roche, SL, Redington, AN. Right ventricle: wrong targets? Another blow for pharmacotherapy in congenital heart diseases. Circulation
2013; 127: 314–316.